Adial制药 ADIL 深 沪
等待开盘 01-12 09:30:00 美东时间
0.242
+0.009
+3.64%
华盛通- 最 高0.2471
- 今 开0.239
- 成交量 25.83万股
- 最 低 0.2301
- 昨 收 0.2335
- 总市值 528.24万
- 52周最高 1.30
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.2165
- 委 比 91.75%
- 总股本 2182.82万
- 历史最高 236.00
- 量 比 0.64
- 振 幅 7.28%
- 历史最低 0.2165
- 每 手 1
- 风险率 0.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Adial Pharmaceuticals announces immediate resignation of board director
Adial Pharmaceuticals ( ($ADIL) ) has issued an update. On January 5, 2025, Adi...
01-07 05:50
Adial Pharmaceuticals Secures $2.86M As Investor Exercises 9.2M Warrants At $0.31; Company To Issue 13.8M New Series F Warrants At Same Price
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today
2025-11-26 21:04
Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Adial Pharmaceuticals provided a business update and financial results for Q3 2025, highlighting progress on AD04, a Phase 3 drug for Alcohol Use Disorder (AUD). Key milestones include a successful End of Phase 2 meeting with the FDA, advancing toward Phase 3 development, and partnerships with Genomind for precision medicine testing. AD04 targets biomarker-positive AG+ patients, identified via a genetic test. The company's cash reserves were $4.6...
2025-11-14 13:30
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
Adial Pharmaceuticals CEO Cary Claiborne appeared on the Emmy Award-winning Big Biz Show, which aired nationally on Fox Business, NBCUniversal, and Time Warner Cable, as well as globally on 175 countries via radio and streaming platforms. Adial is focused on developing treatments for addiction, with its lead drug AD04 showing promise in reducing alcohol consumption in heavy drinkers and potentially treating other addictive disorders like opioid u...
2025-10-17 13:00
Adial Pharma Completes Analytical Validation Of Cheek Swab Collection Method For Testing Patients For Both Clinical Trial Usage As Well As Future Commercial Application
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today
2025-10-09 20:40
Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution
Adial Pharmaceuticals announced the successful completion of analytical validation for a cheek swab collection method to test patients for AD04 development. This method identifies SNPs in the serotonergic system, enabling a patient-friendly companion diagnostic test for clinical trials and commercial use. The partnership with Genomind validated the assay for accuracy, reproducibility, and robustness, achieving 100% concordance. AD04 aims to treat...
2025-10-09 12:30
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
2025-10-01 20:13
Maxim Group Upgrades Adial Pharmaceuticals to Buy, Announces $1.5 Price Target
Maxim Group analyst Jason McCarthy upgrades Adial Pharmaceuticals (NASDAQ:ADIL) from Hold to Buy and announces $1.5 price target.
2025-09-30 20:32
Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder
Adial Pharmaceuticals received FDA backing for its Phase 3 AD04 trial, including endpoints and strategies for targeted populations in Alcohol Use Disorder treatment.
2025-09-16 20:03
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
Adial Pharmaceuticals received positive FDA feedback on their Phase 3 clinical trial design for AD04 in treating Alcohol Use Disorder (AUD). FDA supported the adaptive trial design, biomarker stratification, and efficacy endpoints, including zero heavy drinking days in months 5 and 6. AD04 aims to target AG+ biomarker-positive patients, with plans for streamlined and rigorous Phase 3 development. The milestone strengthens Adial's position for reg...
2025-09-16 12:00
